PharmaEngine
4162.TWO
3.03 USD
-0.09
-2.88%
p
Overview
Last close
3.03 usd
Market cap
435.98M usd
52 week high
3.68 usd
52 week low
2.42 usd
Target price
3.62 usd
Valuation
P/E
8.258
Forward P/E
N/A
Price/Sales
5.7225
Price/Book Value
2.6741
Enterprise Value
318.95M usd
EV/Revenue
4.1953
EV/EBITDA
4.8727
Key financials
Revenue TTM
76.03M usd
Gross Profit TTM
74.59M usd
EBITDA TTM
61.91M usd
Earnings per Share
0.37 usd
Dividend
0.18 usd
Total assets
178.36M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
